What is C1-Esterase Inhibitor (C1INH)?
C1-esterase inhibitor (C1INH) is a serine protease inhibitor (serpin) that functions as the primary regulator of multiple inflammatory cascade systems in the body, including the complement, contact (kallikrein-kinin), coagulation, and fibrinolytic pathways. 1
Molecular Structure and Biochemistry
C1INH is a heavily glycosylated single-chain glycoprotein consisting of 478 amino acids plus a 22-residue signal peptide, with an apparent molecular weight of 105 kD 2. The protein is organized into two functional domains:
- N-terminal domain (first 100 amino acids): Contains most of the N- and O-linked carbohydrates (26-35% of total molecular weight)
- C-terminal domain (carboxy 378 amino acids): Contains the active site in a stressed loop conformation typical of serpins 1
The gene encoding C1INH, named SERPING1, is located on chromosome 11 (p11.2-q13) and contains 8 exons and 7 introns 1.
Mechanism of Action
C1INH functions as a "molecular mousetrap" or suicide inhibitor, forming irreversible 1:1 stoichiometric complexes with target proteases 1. When cleaved by its target protease, C1INH undergoes large-scale conformational rearrangement, trapping and inactivating the protease. The entire C1INH-protease complex is then cleared from circulation 1.
Target Proteases
C1INH is the only known inhibitor for several critical proteases 1, 2:
- Complement system: C1r, C1s (classical pathway), and mannose-binding lectin pathway proteases
- Contact system: Plasma kallikrein and activated Factor XII (Hageman factor)
- Coagulation cascade: Factor XIa (main inhibitor) and Factor XIIa
- Fibrinolytic system: Plasmin 1, 2
Clinical Significance
Hereditary Angioedema (HAE)
The most well-established clinical relevance of C1INH is in HAE, an autosomal dominant disease caused by mutations in the SERPING1 gene 1. More than 250 different mutations have been identified in patients with HAE 1.
Two main types exist:
- Type I HAE (85% of cases): Low antigenic levels of C1INH
- Type II HAE (15% of cases): Normal or elevated antigenic levels but dysfunctional protein 1
Normal plasma concentration of C1INH in healthy individuals is approximately 270 mg/L 2.
Pathophysiology of Angioedema
Bradykinin is the primary mediator of swelling in HAE patients 1. When C1INH is deficient or dysfunctional, uncontrolled activation of the contact system leads to excessive bradykinin generation, resulting in increased vascular permeability and angioedema 1, 2.
Acquired C1INH Deficiency
This condition results from enhanced catabolism of C1INH rather than genetic mutations 1. It typically presents in middle-aged or older patients without family history and may be associated with:
- Underlying lymphoproliferative malignancies
- Autoantibodies against C1INH
- Systemic lupus erythematosus 1
Distinguished from hereditary forms by low C1q levels (normal in HAE types I and II) 1.
Therapeutic Applications
FDA-Approved Uses
C1INH concentrates (such as BERINERT) are plasma-derived, purified products approved for acute treatment of HAE attacks and prophylaxis 2. The standard dose for acute attacks is 20 IU/kg body weight 2.
Broader Anti-Inflammatory Properties
Beyond HAE, C1INH demonstrates therapeutic potential in multiple conditions due to its broad regulatory effects on inflammatory cascades 3, 4, 5:
- Sepsis and endotoxin shock
- Ischemia-reperfusion injury
- Thromboembolism
- Transplantation
- Severe COVID-19 complications
The rationale stems from C1INH's ability to control multiple proinflammatory pathways simultaneously, particularly in conditions where complement and contact system activation contribute to pathology 3, 4, 5.
Important Clinical Considerations
C1INH can be inactivated locally in inflamed tissues by proteolytic enzymes (such as elastase) released from activated neutrophils or bacteria, leading to increased local activation of host defense systems despite adequate systemic levels 5. This explains why replacement therapy may be beneficial even when systemic C1INH levels appear adequate.
In cases of overwhelming proteolytic activation, C1INH can be cleaved into a modified inactive form without forming a complex with or inhibiting the protease, effectively depleting functional C1INH 1.